Fresenius SE & Co. KGaA

Key risks and downside factors

Fresenius operates across hospital services, dialysis-related care, and medical products—hospital management, perfusion and nutrition support, and medical devices—positioning itself as an integrated healthcare services and device competitor [2]. The competitive landscape includes Fresenius Medical Care in dialysis, DaVita in renal services, Baxter International in medical products, Siemens Healthineers in diagnostics and devices, and Roche across pharma and diagnostics, all with overlapping market exposure [7][21][12][8][14]. The company faces material headwinds: reimbursement and regulatory shifts that can move the needle quickly, sustained pressure from larger device and services firms, the operational drag from hospital management and acquisition integration, and meaningful sensitivity to currency fluctuations and geographic shifts in its financing mix [2][1][2][10].

• Hospital and renal care operators face reimbursement and regulatory shifts that could meaningfully compress both revenue and margins.
• The company faces intense competition from large, diversified players—Baxter, Siemens Healthineers, DaVita, and Roche among them—that have both the scale and resources to pressure pricing and erode market share [1][12][8][21].
• Operational and integration risks stemming from hospital-management activities and acquisitions could result in execution shortfalls or cost overruns.
• Currency swings and macroeconomic shifts across different markets pose real exposure. Add in refinancing risks—the kind that can quietly compress cash flow and make debt servicing tighter than expected—and you've got layers worth tracking.

Competitive landscape

Fresenius SE & Co. KGaA (FRE.XETRA) operates across hospital management, dialysis and renal care, pharmaceuticals and infusion therapy, plus broader healthcare services—a sprawl that gives it genuine scale across both care delivery and product lines. The competitive field is fragmented: Baxter and DaVita in renal care, Siemens Healthineers in diagnostics and devices, each nibbling at different corners of the business. That breadth cushions it from any single market downturn, though it trades that safety for complexity—regulatory requirements, reimbursement pressures, and operational execution challenges now ripple across multiple jurisdictions at once.

Performance Figures of Fresenius SE & Co. KGaA

in EUR

Historical valuation trends

How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.

Frequently Asked Questions

Key Metrics

Valuation Metrics

Profitability Metrics

Growth Metrics

Dividend history

Long-term record of paid dividends (amount per share and dividend yield at the time of payment).

Earnings history & estimates

Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.

Key financial figures

All figures in EUR

Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.